Netflix's Growth Undervalued Despite Strong Global Content, AI Leadership, Deutsche Bank Says

On October 6th, shares of biotech company Caribou Biosciences (CRBU.O) fell by 36.1% in after-hours trading to $0.73. The company announced it is exploring potential sale, merger, or other options to unlock shareholder value. Caribou plans to discontinue the development of its experimental cell therapy vispa-cel for a certain blood cancer, as well as CB-011 for treating the bone marrow cancer—multiple myeloma. The company stated that vispa-cel is ready for clinical trials, and it has reached an agreement with the FDA on the design for late-stage clinical trials. However, the difficult financing environment for allogeneic CAR-T therapies has made it challenging to raise the necessary funds to advance these projects. Caribou also intends to lay off employees and cut costs; according to its report, as of June 30, 2026, the company held $113.8 million in cash, cash equivalents, and marketable securities. As of the previous trading day’s close, the stock had fallen about 29% year-to-date. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several languages. As automated translations may contain errors or lack context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for reader convenience. Reuters assumes no liability for any harm or loss from use of the automated translation feature.)

This article was automatically generated using Dow Jones technology. Shares of Vanguard FTSE Emerging Markets ETF were flat at $60.62 Tuesday on what proved to be an overall favorable trading session for the U.S. stock market, with the S&P 500 Index rising 0.6% to 7,818.93. This was the fund's third consecutive day of gains. The ETF's shares closed 1.5% below the 52-week high of $61.53 seen on September 4, 2026. Trading volume was 4,661,177, compared to the 65-day average trading volume of 7,016,590. As of October 5, the fund's net asset value totaled $60.76 per share. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 06, 2026 16:37 ET (20:37 GMT)

This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Novavax Inc. shed 9.9% to $11.32 on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 0.4% to 27,599.79 and the Dow Jones Industrial Average rising 0.5% to 51,521.28. Novavax Inc. closed 15.4% below its 52-week high of $13.39, which the company achieved on October 5th. The stock underperformed when compared to some of its peers, as Johnson & Johnson rose 0.7% to $254.78, Pfizer Inc. rose 0.3% to $27.50, and Merck & Co. Inc. rose 1.72% to $141.94. Trading volume totaled 19.3 million, compared to the 50-day average of 5.3 million. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 06, 2026 16:33 ET (20:33 GMT)

Evogene will hold a special general meeting of shareholders in Rehovot, Israel on Nov. 10, 2026. Shareholders will vote on electing Oz Adler and Dr. Adi Zuloff-Shani to the board. Ballots will also cover the election of Itay Maroz and Shahar Zadok, subject to approval of a cooperation agreement. The meeting will also vote on a cooperation agreement between Evogene and L.I.A. Pure Capital and Invest-Pro Shukai Hon. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004722), on October 06, 2026, and is solely responsible for the information contained therein.